dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Román Alonso, Macarena |
dc.contributor.author | Luque García, Antonio |
dc.contributor.author | Fajardo, Carlos Alberto |
dc.contributor.author | Gros Vidal, Alena |
dc.contributor.author | Arribas López, Joaquin Vicente |
dc.contributor.author | Arenas Lahuerta, Enrique Javier |
dc.contributor.author | Martínez-Sabadell, Alex |
dc.contributor.author | Rius Ruiz, Irene |
dc.contributor.author | Escorihuela Baez, Marta |
dc.date.accessioned | 2022-01-25T12:14:18Z |
dc.date.available | 2022-01-25T12:14:18Z |
dc.date.issued | 2021-02-23 |
dc.identifier.citation | Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021 Feb 23;12:1237. |
dc.identifier.issn | 2041-1723 |
dc.identifier.uri | https://hdl.handle.net/11351/6893 |
dc.description | Immunoteràpia del càncer; Resistència terapèutica del càncer |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | Nature Communications;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Immunoteràpia |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /immunology |
dc.subject.mesh | Drug Resistance, Neoplasm |
dc.title | Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41467-021-21445-4 |
dc.subject.decs | neoplasias |
dc.subject.decs | /inmunología |
dc.subject.decs | resistencia a los antineoplásicos |
dc.relation.publishversion | https://doi.org/10.1038/s41467-021-21445-4 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Arenas EJ, Rius Ruiz I] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. [Martínez-Sabadell A, Román Alonso M, Escorihuela M, Luque A] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fajardo CA, Gros A] Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain |
dc.identifier.pmid | 33623012 |
dc.identifier.wos | 000623781900011 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |